Amgen CEO Bradway says AI reshapes drug discovery and development

Amgen Inc.

Amgen Inc.

AMGN

0.00
  • Amgen CEO Bob Bradway told Bain’s Winning with AI podcast that AI is reshaping biotechnology, with broad impact across the drug lifecycle.
  • Bradway said the company invested early in AI and data science, positioning it to apply the technology across its operations.
  • He framed AI as a catalyst for change in how medicines are discovered, developed, manufactured, and delivered to patients.
  • The interview focused on scaling organizational transformation to support wider AI deployment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.